Frazier Life Sciences Funds Detail Significant Investment in Mirum Pharmaceuticals Following Bluejay Acquisition
MIRM has more than doubled off its 52-week low of $36.88.
Summary
Frazier Life Sciences funds disclosed a significant $66.76 million investment in Mirum Pharmaceuticals through a private placement, acquiring shares and warrants at a discount following the Bluejay Therapeutics acquisition.
Key Events · Ownership and Investor Activity · MIRM
-
Significant Institutional Investment
Frazier Life Sciences funds acquired approximately $66.76 million in Mirum Pharmaceuticals common stock and pre-funded warrants.
-
Acquisition Financing Details
The investment was part of a private placement on January 23, 2026, immediately following the completion of Mirum's acquisition of Bluejay Therapeutics, as previously disclosed on January 26, 2026.
-
Discounted Purchase Price
Shares and warrants were purchased at $68.48 per unit, representing a discount compared to the current stock price of $99.27.
-
Updated Beneficial Ownership
The filing updates the Frazier group's beneficial ownership, with Patrick J. Heron now holding 6.8% of the common stock.
Analysis · MIRM · Life Sciences
This Schedule 13D/A provides crucial details on the financing of Mirum Pharmaceuticals' recently completed acquisition of Bluejay Therapeutics. The Frazier Life Sciences group, a significant institutional investor, acquired approximately $66.76 million in common stock and pre-funded warrants on January 23, 2026, as part of a private placement. While these shares and warrants were purchased at a notable discount to the current market price, this substantial capital infusion from a prominent life sciences investor group signals confidence in Mirum's strategic direction and the value of the Bluejay acquisition. The filing also updates the Frazier group's overall beneficial ownership in Mirum.
At the time of this filing, MIRM was trading at $99.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $36.88 to $99.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.